Skip to main content

Advertisement

SpringerLink
Log in

Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Chronic myeloid leukemia (CML) is a rare disease among children. A retrospective study was conducted from November 2002 to March 2019 at a single institution in China. A total of 36 pediatric CML patients (25 male and 11 female) were enrolled. Median follow-up time was 51 months (range 8–144), and 5-year overall survival and event-free survival were 95.5 ± 4.4% and 88.9 ± 6.0%, respectively. Among the 25 patients whose response to imatinib mesylate (IM) was regularly monitored, 92.0% achieved complete hematologic response at 3 months, 80.0% achieved complete cytogenetic response at 12 months, and 64.0% achieved major molecular response at 18 months after IM therapy. A higher WBC count at diagnosis was associated with failure to achieve early molecular response (EMR). Height standard deviation score after long-term treatment was significantly and positively correlated with age at diagnosis and at the start of IM therapy. Overall, IM therapy was effective in treating pediatric CML, and WBC count at diagnosis might be an ideal predictor of EMR. Moreover, retardation of height and weight growth due to IM tended to affect patients younger than 9 years old at diagnosis, and longitudinal growth might normalize further into treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics. 2005;116:140–3.

    Article  PubMed  Google Scholar 

  2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    Article  CAS  PubMed  Google Scholar 

  3. Hijiya N, Millot F, Suttorp M. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions. Pediatr Clin N Am. 2015;62:107–19.

    Article  Google Scholar 

  4. Suttorp M, Schulze P, Glauche I, Gohring G, von Neuhoff N, Metzler M, et al. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia. 2018;32:1657–69.

    Article  CAS  PubMed  Google Scholar 

  5. Lakshmaiah KC, Bhise R, Purohit S, Abraham LJ, Lokanatha D, Suresh TM, et al. Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate. Leukemia Lymphoma. 2012;53:2430–3.

    Article  CAS  PubMed  Google Scholar 

  6. Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol. 2011;29:2827–32.

    Article  CAS  PubMed  Google Scholar 

  7. Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, et al. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol. 2015;26:185–92.

    Article  CAS  PubMed  Google Scholar 

  8. Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood. 2012;119:1821–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gurrea Salas D, Glauche I, Tauer JT, Thiede C, Suttorp M. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients? Ann Hematol. 2015;94:1363–71.

    Article  PubMed  Google Scholar 

  10. Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127:392–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Millot F, Guilhot J, Baruchel A, Petit A, Leblanc T, Bertrand Y, et al. Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. Eur J Cancer. 2014;50:3206–11.

    Article  CAS  PubMed  Google Scholar 

  12. Shima H, Tokuyama M, Tanizawa A, Tono C, Hamamoto K, Muramatsu H, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr. 2011;159:676–81.

    Article  CAS  PubMed  Google Scholar 

  13. Samis J, Lee P, Zimmerman D, Suttorp M, Hijiya N. The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy for chronic myelogenous leukemia. Pediatr Blood Cancer. 2017;64. https://doi.org/10.1002/pbc.26703

  14. Mahon F-X, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35.

    Article  CAS  PubMed  Google Scholar 

  15. Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747–57.

    Article  CAS  PubMed  Google Scholar 

  16. Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Chronic myeloid leukemia, version 1. 2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:1108–35.

    Article  PubMed  Google Scholar 

  17. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Zong XN, Li H. Construction of a new growth references for China based on urban Chinese children: comparison with the WHO growth standards. PLoS ONE. 2013;8:e59569.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kong XL, Xiao SP, Huang XH, et al. Quantitative analysis of height and weight in children with beta-thalassemia major and the associated factor [J]. Chin J Child Health Care. 2018;26(6):622–5.

    Google Scholar 

  20. Gore L, Kearns PR, de Martino ML, Lee N, De Souza CA, Bertrand Y, et al. Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial. J Clin Oncol. 2018;36:1330–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hijiya N, Suttorp M. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2019;133:2374–84.

    Article  CAS  PubMed  Google Scholar 

  22. Tanizawa A. Optimal management for pediatric chronic myeloid leukemia. Pediatr Int. 2016;58:171–9.

    Article  PubMed  Google Scholar 

  23. Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma. 2013;54:1411–7.

    Article  PubMed  Google Scholar 

  24. Shi YM, Liu S. Sex ratio at birth in China: changes and implications [J]. Popul Res. 2015;39:35–48.

    Google Scholar 

  25. Cwynarski K, Roberts IAG, Iacobelli S, van Biezen A, Brand R, Devergie A, et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;102:1224–31.

    Article  CAS  PubMed  Google Scholar 

  26. Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukemia: past, present, and future. Am J Hematol. 2009;84:287–93.

    Article  CAS  PubMed  Google Scholar 

  27. Karalexi MA, Baka M, Ryzhov A, Zborovskaya A, Dimitrova N, Zivkovic S, et al. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America. Eur J Cancer Oxf Engl. 1990;2016(67):183–90.

    Google Scholar 

  28. El-Alfy MS, Al-Haddad AM, Hamed AA. Management of CML in the pediatric age group: imatinib mesylate or SCT. J Egypt Natl Canc Inst. 2010;22:227–32.

    PubMed  Google Scholar 

  29. Giona F, Putti MC, Micalizzi C, Menna G, Moleti ML, Santoro N, et al. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. Br J Haematol. 2015;170:398–407.

    Article  CAS  PubMed  Google Scholar 

  30. Ganta RR, Nasaka S, Gundeti S. Impact of imatinib adherence on the cytogenetic response in pediatric chronic myeloid leukemia—chronic phase. Indian J Pediatr. 2016;83:1009–12.

    Article  PubMed  Google Scholar 

  31. Giona F, Saglio G, Santopietro M, Menna G, Putti MC, Micalizzi C, et al. Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib. Br J Haematol. 2018;180:895–8.

    Article  PubMed  Google Scholar 

  32. Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, Busfield SJ, et al. TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia. 2016;30:1263–72.

    Article  CAS  PubMed  Google Scholar 

  33. Kok CH, Yeung DT, Lu L, Watkins DB, Leclercq TM, Dang P, et al. Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Adv. 2019;3:1610–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. de la Fuente J, Baruchel A, Biondi A, de Bont E, Dresse MF, Suttorp M, et al. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol. 2014;167:33–47.

    Article  PubMed  Google Scholar 

  36. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17.

    Article  CAS  PubMed  Google Scholar 

  37. Samis J, Lee P, Zimmerman D, Arceci RJ, Suttorp M, Hijiya N. Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia. Pediatr Blood Cancer. 2016;63:1332–8.

    Article  PubMed  Google Scholar 

  38. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947–52.

    Article  CAS  PubMed  Google Scholar 

  39. Narayanan KR, Bansal D, Walia R, Sachdeva N, Bhansali A, Varma N, et al. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. Pediatr Blood Cancer. 2013;60:1148–53.

    Article  CAS  PubMed  Google Scholar 

  40. Bansal D, Shava U, Varma N, Trehan A, Marwaha RK. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer. 2012;59:481–4.

    Article  PubMed  Google Scholar 

  41. Rastogi MV, Stork L, Druker B, Blasdel C, Nguyen T, Boston BA. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatr Blood Cancer. 2012;59:840–5.

    Article  PubMed  Google Scholar 

  42. Giona F, Mariani S, Gnessi L, Moleti ML, Rea M, De Vellis A, et al. Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty. Haematologica. 2013;98:e25-27.

    Article  PubMed  PubMed Central  Google Scholar 

  43. de Bruijn CMA, Millot F, Suttorp M, Borisevich M, Brons P, Lausen B, et al. Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study. Br J Haematol. 2019;185:718–24.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank the patients for participating in this study.

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China

    Yuli Cai, Chao Liu, Ye Guo, Xiaojuan Chen, Li Zhang, Yumei Chen, Yao Zou, Wenyu Yang & Xiaofan Zhu

Authors
  1. Yuli Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ye Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaojuan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yumei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yao Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wenyu Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiaofan Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaofan Zhu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 17 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cai, Y., Liu, C., Guo, Y. et al. Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China. Int J Hematol 113, 413–421 (2021). https://doi.org/10.1007/s12185-020-03042-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-020-03042-1

Keywords

Search

Navigation